1221721-86-3

Basic information

• Product Name: 3-broMo-N-{6-[(2R,6S)-2,6-diMethyl-1,4-oxazinan-4-yl]-3-pyridinyl}-2-MethylbenzenecarboxaMide
• Synonyms: 3-broMo-N-{6-[(2R,6S)-2,6-diMethyl-1,4-oxazinan-4-yl]-3-pyridinyl}-2-MethylbenzenecarboxaMide;3-BroMo-N-(6-((2R,6S)-2,6-diMethylMorpholino)pyridin-3-yl)-2-MethylbenzaMide;3-bromo-N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methylbenzamide compound with 4-benzyl-2-hydroxymorpholin-3-one (1:1);3-bromo-N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methylbenzamide
• CAS NO: 1221721-86-3
• Molecular Formula: C19H22BrN3O2
• Molecular Weight: 404.30088
• Mol File: 1221721-86-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 492.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.359±0.06 g/cm3(Predicted)
• PKA: 12.18±0.70(Predicted)
• CAS DataBase Reference: 3-broMo-N-{6-[(2R,6S)-2,6-diMethyl-1,4-oxazinan-4-yl]-3-pyridinyl}-2-MethylbenzenecarboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-broMo-N-{6-[(2R,6S)-2,6-diMethyl-1,4-oxazinan-4-yl]-3-pyridinyl}-2-MethylbenzenecarboxaMide(1221721-86-3)
• EPA Substance Registry System: 3-broMo-N-{6-[(2R,6S)-2,6-diMethyl-1,4-oxazinan-4-yl]-3-pyridinyl}-2-MethylbenzenecarboxaMide(1221721-86-3)

Safety Data

• Hazardous Substances Data: 1221721-86-3(Hazardous Substances Data)

Usage

General Description

3-bromo-N-{6-[(2R,6S)-2,6-dimethyl-1,4-oxazinan-4-yl]-3-pyridinyl}-2-methylbenzenecarboxamide is a chemical compound with the molecular formula C18H22BrN3O2. It is a carboxamide derivative containing a bromo and methyl group, as well as a pyridinyl and oxazinan-4-yl substituent. 3-broMo-N-{6-[(2R,6S)-2,6-diMethyl-1,4-oxazinan-4-yl]-3-pyridinyl}-2-MethylbenzenecarboxaMide is used in medicinal and pharmaceutical research and is a potential drug candidate for the treatment of certain diseases or disorders. It may exhibit a range of biological activities and pharmacological effects due to its unique chemical structure, making it a subject of interest in drug discovery and development.

Upstream product

• 956699-06-2 (2S,6R)-2,6-dimethyl-4-(5-aminopyridin-2-yl)morpholine 
• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 260447-04-9 (2S,6R)-2,6-dimethyl-4-(5-nitropyridin-2-yl)morpholine 
• 141-91-3 cis-2,6-dimethylmorpholine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 7697-26-9 3-bromo-4-methylbenzoic acid 

Downstream Products

• 1218778-77-8 N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4’-(trifluoromethoxy)-[1,1‘-biphenyl]-3-carboxamide diphosphate 
• 956697-53-3 Erismodegib 

Relevant articles and documents

An environmentally responsible 3-pot, 5-step synthesis of the antitumor agent sonidegib using ppm levels of Pd catalysis in water

The current industrial approach to sonidegib utilizes wasteful organic solvents and relies on high loadings of endangered Pd. This anticancer drug can now be synthesized in 5 steps using only 3 pots, along with ppm levels of a Pd catalyst, all done in water at ambient temperatures.

Sonidegib phosphate

Sonidegib phosphate (LDE-225) is a potent, orally bioavailable, selective inhibitor of smoothened protein, a key downstream transducer of the hedgehog signaling pathway. This pathway has been recently associated with cancer development and progression in several tumor types, and components of this pathway have been regarded as targets for the development of new anticancer agents. In preclinical studies, sonidegib bound to smoothened protein with high affinity, leading to dose-related inhibition of hedgehog signaling, ultimately resulting in tumor growth arrest and regression. In early clinical studies, sonidegib showed a favorable safety profile and demonstrated promising antitumor activity, mainly in basal cell carcinoma and medulloblastoma. Ongoing trials are evaluating sonidegib either alone in selected cancer types or in combination with conventional cytotoxic drugs against a broad range of solid tumors.